Picard Medical / SynCardia Highlight Second Successful Total Artificial Heart Bridge to Transplant at UCSF Health

Core Insights - The case highlights the successful use of the SynCardia Total Artificial Heart to bridge a young patient with advanced biventricular heart failure to heart transplantation after 119 days of support [1][2][3] Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which produces the only commercially available total artificial heart technology approved by both the U.S. FDA and Health Canada [5] - The SynCardia Total Artificial Heart is the first artificial heart to receive regulatory approval in both the U.S. and Canada, and it is the most widely used artificial heart globally, with over 2,100 implants performed across 27 countries [5] Industry Context - The successful case at UCSF Health represents the second of five patients who have been bridged to transplantation using the SynCardia Total Artificial Heart, indicating the growing role of total artificial heart therapy in treating patients with severe heart failure [2][3] - The increasing adoption of the SynCardia Total Artificial Heart at leading transplant centers reflects the rising demand for advanced mechanical circulatory support for patients with end-stage heart failure [4]